Gene Logic Announces Enhanced Software for Drug Target Discovery and Compound Safety Assessment
Gene Logic Inc. today announced the launch of its Genesis Enterprise System(R) 3.0 Software to address pharmaceutical industry needs to accelerate drug target discovery and more rapidly assess drug candidate safety. The latest software version offers greater flexibility and new tools enabling researchers to efficiently access, organize, and analyze large amounts of gene expression data associated with clinical, experimental and genomics information.
The Genesis Enterprise System 3.0 Software system is designed to meet the sophisticated and changing needs of drug discovery and development scientists:
— The system is now fully scalable to suit researcher’s needs for dynamic analysis of their own gene expression data, public data, and data contained within Gene Logic’s BioExpress(R) and ToxExpress(R) Systems.
— New data integration tools allow scientists to import multiple gene expression data types, and new data analysis and annotation tools facilitate rapid and thorough compound safety assessment using toxicogenomics.
— The system is now interoperable with Gene Logic’s ASCENTA(R) System 2.0, enabling customers to quickly combine clinical data with gene expression profiling across tissues, diseases, and species to map gene expression to disease.
The latest Genesis System improves the ability of researchers to identify genes associated with disease, assisting in drug target discovery, understanding of disease mechanisms, and identifying clinical biomarker candidates. Researchers also use the system to correlate gene expression with toxicological pathology, which is useful in assessing and verifying treatment effects, identifying potential safety biomarkers, and understanding the mechanisms of toxicity. The system also helps prioritize and validate drug targets through analysis of novel biological pathways.
Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, “Our goal is to provide a complete solutions portfolio that will help our customers efficiently discover and develop new drug targets and efficacious compounds. Gene Logic’s Genesis Enterprise System provides powerful tools for these applications, and new features that will expand drug researchers’ abilities to quickly develop therapeutic strategies to treat human disease. Our improved system is unique in the marketplace and gives our pharmaceutical and biotechnology customers exceptional analytical abilities.”
Gene Logic Overview
Gene Logic is leading the transformation of pharmaceutical research and development with its extensive gene expression databases, pioneering efforts in toxicogenomics, sophisticated bioinformatics expertise, specialty nonclinical services testing capabilities and cutting edge technology program for drug repositioning. Gene Logic technologies and services are used by many of the world’s top pharmaceutical and biotechnology companies. Over 150 organizations and government agencies have benefited from Gene Logic’s diverse portfolio of drug development services, enabling them to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. Founded in 1994, Gene Logic is headquartered in Gaithersburg, Maryland, with additional research and development facilities in Cambridge, Massachusetts, and Berkeley, California. The Company maintains customer support operations in Europe and Asia and currently has about 450 employees worldwide. For more information, visit www.genelogic.com or call toll-free – 1/800/GENELOGIC.
